Last reviewed · How we verify

Cipher Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief

Cipher Pharmaceuticals Inc. pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Spinosad Topical Spinosad Topical marketed Natural insecticide Nicotinic acetylcholine receptors; GABA-gated chloride channels Dermatology
CIP-Isotretinoin CIP-Isotretinoin phase 3 Retinoid Retinoid acid receptors (RAR, RXR) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Actavis Inc. · 1 shared drug class
  2. Army Medical University, China · 1 shared drug class
  3. Bausch Health Americas, Inc. · 1 shared drug class
  4. Center for Sight Las Vegas · 1 shared drug class
  5. Centro Dermatológico Dr. Ladislao de la Pascua · 1 shared drug class
  6. Dr. Emmy Graber · 1 shared drug class
  7. Dr. Reddy's Laboratories Limited · 1 shared drug class
  8. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cipher Pharmaceuticals Inc.:

Cite this brief

Drug Landscape (2026). Cipher Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cipher-pharmaceuticals-inc. Accessed 2026-05-14.

Related